Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY gears up for Phase 3 trial in HR+/HER2- breast cancer

<< Previous

Bullboard Posts

Next >>

Comment by fasttrack5on May 31, 2023 3:02pm

102 Views

Post# 35473265

RE:RE:ONCY gears up for Phase 3 trial in HR+/HER2- breast cancer

jimsenior wrote: @Noteable. Thanks for pointing out this site. Well written piece. The use of the word - teased - was interesting. Time to deliver. Best.

Added another 3000 shares this morning.
looking positive going forward.
I'm betting on it.
just sayin. :)
fast.

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals